Figure 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Changes in immune cell abundance in patients with ICI-related fatigue. Cytotoxic effector CD8⁺GZMB+TBET+ T cells, (A) TcEFF_I and (B) TcEFF_III, are implicated in the Th1-associated pathway and increased in abundance on treatment in patients with ICI-related fatigue. Meanwhile, effector memory T cells, (C) TcEM and (D) Th2EM, decreased in abundance on treatment in patients with ICI-related fatigue. A Wilcoxon signed-rank test was used, *, P <0.05; **, P <0.01; ***, P <0.001.